Drug Profile


Alternative Names: Pharanoxi phosphas

Latest Information Update: 26 Aug 2002

Price : $50

At a glance

  • Originator Lithuanian Oncology Center
  • Class Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Aug 1998 Profile reviewed
  • 11 Apr 1996 Phase-II clinical trials for Cancer in Lithuania (PO)
  • 04 Apr 1996 A study has been added to the therapeutic trials, pharmacodynamics, pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top